Curasight Investor Relations Material
Latest events
Q2 2024
Curasight
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Curasight
Access all reports
Curasight is a clinical stage biopharmaceutical company dedicated to developing uPAR Theranostics for the early detection, diagnosis and treatment of cancer. The company's mission is to make a global impact by harnessing imaging technology that improves diagnosis and correlates to improved long-term patient outcome.
Latest articles
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Novo Nordisk: The Danish Pharmaceutical Titan Revolutionizing Global Healthcare
Novo Nordisk's rise to becoming Europe's largest company, reshaping global healthcare and Denmark's economy.
5 Sep 2024
The Toyota Way: Revolutionizing Global Manufacturing
Explore how Toyota's Lean Manufacturing and Kaizen principles revolutionized production and quality, setting global benchmarks for excellence.
2 Sep 2024
Ticker symbol
CURAS
Country
🇩🇰 Denmark